JL Lennox
About
In The Last Decade
JL Lennox
5 papers receiving 169 citations
Peers
Comparison fields: 5 of 42
- Pharmacology 89
- Pediatrics, Perinatology and Child Health 55
- Infectious Diseases 48
- Oncology 46
- Molecular Biology 41
Countries citing papers authored by JL Lennox
This map shows the geographic impact of JL Lennox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JL Lennox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JL Lennox more than expected).
Fields of papers citing papers by JL Lennox
This network shows the impact of papers produced by JL Lennox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JL Lennox. The network helps show where JL Lennox may publish in the future.
Co-authorship network of co-authors of JL Lennox
This figure shows the co-authorship network connecting the top 25 collaborators of JL Lennox. A scholar is included among the top collaborators of JL Lennox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JL Lennox. JL Lennox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 154 | |
| 2 | Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 (vol 161, pg 461, 2014) | 4 |
| 3 | Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naï ve Patients: 192 Week Results from STARTMRK | 1 |
| 4 | Metabolic Profiles and Body Composition Changes in Treatment-Naï ve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 48-Week Data | 2 |
| 5 | STARTMRK, A Phase III Study of the Safety & Efficacy of Raltegravir (RAL)-Based vs Efavirenz (EFV)-Based Combination Therapy in Treatment-Naïve HIV-Infected Patients | 11 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.